The cost of a hospital-acquired infection is split, often unevenly, among hospitals, government insurance programs, private insurers, and patients themselves. No single party absorbs the full bill. How much each pays depends on the type of infection, the insurance arrangement, and whether the hospital followed proper safety protocols. In many cases, hospitals bear the largest share of unreimbursed costs, but patients and taxpayers are far from unscathed.
What Hospitals Pay Out of Pocket
Hospitals absorb a significant portion of the cost when a patient develops an infection during their stay. Treating drug-resistant staph infections like MRSA-related pneumonia costs roughly $38,505 per patient. A C. difficile infection runs about $24,205 per case, and if it comes back (which it often does), that adds another $10,580. These are not small line items, especially for hospitals managing dozens or hundreds of these cases each year.
The critical question is how much of that cost the hospital can recover through insurance reimbursement. Research modeling different payment scenarios found that when private insurers pay at standard Medicare rates, hospitals recover only about 27% to 28% of their excess costs for bloodstream infections and urinary tract infections. Even when private insurers pay at double Medicare rates, hospitals still only recoup around 55% of the extra costs. The remaining balance comes directly out of the hospital’s operating budget.
The payment structure matters enormously here. Under per-diem arrangements, where insurers pay a daily rate, hospitals recover a much higher share: 71% of excess bloodstream infection costs and over 88% of excess urinary tract infection costs among privately insured patients. Under bundled payment models (where the hospital gets one lump sum for the entire episode of care), an infection that extends the stay or requires extra treatment can be a pure financial loss.
How Medicare Penalizes Hospitals
Medicare has built two overlapping systems designed to make hospitals, not taxpayers, pay for preventable infections.
The first is a list of 14 categories of hospital-acquired conditions that Medicare refuses to reimburse at the higher payment tier. If a patient develops one of these conditions during their stay and it wasn’t present on admission, Medicare pays the hospital at the lower diagnosis-related group rate. The list includes catheter-associated urinary tract infections, vascular catheter-associated infections, surgical site infections after procedures like coronary artery bypass grafts, hip and knee replacements, bariatric surgery, and certain spine and orthopedic surgeries. It also covers non-infection events like objects left inside a patient after surgery, serious pressure ulcers, and patient falls with injuries.
The second mechanism is the Hospital-Acquired Condition Reduction Program, which ranks every hospital in the country on infection performance. Hospitals that fall in the worst-performing 25% receive a 1% reduction across all their Medicare payments for that fiscal year. That penalty applies to the hospital’s entire Medicare revenue, not just the patients who got infections. For a large hospital system, 1% of total Medicare reimbursement can translate to millions of dollars annually.
On top of these penalties, the Hospital Value-Based Purchasing Program withholds a percentage of every participating hospital’s payments and redistributes that money based on quality scores, including infection rates. High-performing hospitals can earn back more than what was withheld. Poor performers lose money. The net effect is a transfer of funds from hospitals with high infection rates to those with low ones.
What Private Insurers Cover
Private insurance policies vary widely in how they handle hospital-acquired infections. Unlike Medicare, which has a standardized national policy, private payers use a patchwork of payment methods. Some pay per diem (a daily rate for each day in the hospital), some use bundled payments similar to Medicare’s system, and some negotiate case-by-case. In Los Angeles, for instance, per-diem arrangements are common among private insurers, while in Indianapolis they’re rare. Reimbursement rates also swing dramatically, from matching Medicare rates to paying more than double.
Most major private insurers have followed Medicare’s lead in refusing to pay extra for certain preventable complications. But enforcement varies, and hospitals with strong negotiating positions can sometimes recoup more of their costs through higher baseline rates. The practical result is that a hospital-acquired infection’s financial impact on the insurer depends heavily on the specific contract between that insurer and that hospital.
What Patients End Up Paying
Patients are rarely shielded entirely from the costs of an infection they didn’t cause. Research on Medicare Advantage enrollees who developed C. difficile infections found that patients paid an average of $396 more in out-of-pocket costs within two months of their infection compared to similar patients who stayed infection-free. For patients who needed hospitalization for a healthcare-associated infection, that figure rose to $514. Patients hospitalized for community-associated cases faced even higher out-of-pocket costs, averaging $970.
These costs come from several sources. An infection typically adds about 3.5 extra days in the hospital, and those additional days generate copays, coinsurance charges, and facility fees that flow through to the patient. Total healthcare costs (combining what the insurer and patient both pay) averaged $28,762 in excess charges for hospitalized patients with healthcare-associated C. difficile. The patient’s direct share is a fraction of that total, but hundreds of dollars in unexpected medical bills can be a serious burden, particularly for people already managing a health crisis.
Patients with high-deductible plans or those who haven’t yet met their annual deductible face even steeper exposure, since a larger portion of any additional charges lands on them directly.
When Hospitals Face Legal Liability
Lawsuits add another layer of financial accountability. Patients can pursue malpractice claims against hospitals for acquired infections, but winning requires proving the hospital was at fault. Courts look for specific failures: ignoring hygiene and sterilization protocols, not taking extra precautions for patients with weakened immune systems or chronic conditions like diabetes, poor sanitation of operating rooms, or improperly sterilized surgical instruments.
The legal burden of proof falls on the hospital. To defend itself, a facility must document that it followed all relevant guidelines and best practices for infection prevention, properly sterilized equipment, and met regulatory requirements. A hospital that can show thorough compliance with established protocols has a strong defense. One that cannot produce that documentation faces significant legal exposure. Analysis of civil court judgments in malpractice cases found that fault-based liability most commonly arose from failures in basic, well-established hygiene practices rather than from unusual or unforeseeable complications.
The Bigger Picture
The financial burden of hospital-acquired infections is designed to fall primarily on hospitals, as an incentive to prevent them. Medicare’s penalties, private insurer pushback, and malpractice risk all point costs in the hospital’s direction. But the system is imperfect. Hospitals rarely absorb 100% of the excess costs. Patients pay more in copays and extended stays. Taxpayers fund the Medicare system that covers much of the treatment. And insurers pass their costs along through higher premiums.
In practice, everyone pays something. The policy trend over the past 15 years has been to shift more of that cost onto hospitals, under the theory that they’re the only party with the power to actually prevent infections. Whether that financial pressure has meaningfully reduced infection rates remains a separate, and much debated, question.